Dermatology Times March 2025 Recap

Clearances, Approvals, Updates, and Recommendations

FDA Alerts of New Independent Testing for Benzoyl Peroxide Acne Products, Additional Voluntary Recalls

The agency shared details of additional voluntary recalls and its plans to release full results of its independent testing in the coming months.

Journey Medical Launches Emrosi, a Dual-Release Minocycline for Rosacea

The lowest-dose oral minocycline for rosacea is now available by prescription following FDA approval in November 2024.

Expert Recommendations for Personalized AD Treatment

An expert panel of clinicians provided insights on first-line treatments, maintenance strategies, and flare management for AD.

Big Studies and Big Data

Apogee Therapeutics' APG990 Demonstrates Extended Half-Life and Favorable Tolerability in Interim Phase 1 Data

APG990 showed a 60-day half-life and favorable safety, supporting potential 3-6 month maintenance dosing for atopic dermatitis.

Journey Medical Publishes Full Phase 3 Trial Results for DFD-29

The findings of the MVOR-1 and MVOR-2 studies are published in JAMA Dermatology, supporting the rosacea drug’s recent FDA approval.

New Study Explores Benzoyl Peroxide-Related Adverse Events and Potential Neoplasm Signals

Published in JID, the study analyzes data from the FDA’s FAERS database to examine cases of neoplasms—including skin and breast cancers—potentially associated with benzoyl peroxide use.

Torqur AG Reports Promising Phase 2 Results for Bimiralisib Gel in Actinic Keratosis

The phase 2 trial of bimiralisib gel shows promising efficacy and safety for actinic keratosis, with up to 70% lesion clearance.

Tapinarof Extends Symptom-Free Periods in Patients with AD

The ADORING 3 study demonstrated that tapinarof cream 1% maintains low disease activity in patients with AD for an average of 79.8 days post-treatment.

Late Breaking: Data From Pivotal Trial Reports Dupilumab Effective for Bullous Pemphigoid

Late breaking data points to positive data for dupilumab for bullous pemphigoid.

Medicus Reports Promising Interim Results for Non-Invasive BCC Treatment

Medicus’ previous phase 1 study confirmed D-MNA’s safety, with some participants achieving complete BCC clearance.

Icotrokinra Demonstrates Promise in Phase 3 ICONIC-LEAD and ICONIC-ADVANCE for Plaque Psoriasis

Johnson & Johnson’s JNJ-2113 showed promise for PsO, achieving high skin clearance with a strong safety profile.

InflaRX Presents Efficacy and Safety Data on Vilobelimab at AAD 2025

Efficacy, safety, and pharmacokinetic data support the use of vilobelimab in treating pyoderma gangrenosum and hidradenitis suppurativa.

Lebrikizumab Shows 3-Year Sustained Efficacy in AD

The study found half of the patients receiving once-monthly lebrikizumab achieved complete skin clearance at 3 years, with 87% maintaining near-clearance.

Late-Breaking ESK-001 Data from the OLE STRIDE Trial Presented at AAD 2025

New results from Alumis show a positive clinical response and safety profile after 52 weeks of treatment for patients with plaque psoriasis.

Market, Pharma, and Specialty News

New Survey By LEO Pharma and Ipsos Highlights Diagnostic, Treatment Gaps in Chronic Hand Eczema

A new survey reveals widespread misunderstanding and lack of effective treatments in chronic hand eczema.

ICYMI: Quoin Files New Rapamycin Patent Applications for Rare Disease Treatment

The novel formulations will harness Quoin’s Invisicare technology to treat microcystic lymphatic malformations, venous malformations, and angiofibromas.

AAD Announces Newly Appointed Leadership Officers

In addition to Taylor, several other new leaders have been appointed to key roles within the AAD to help drive its mission of advancing dermatology.

L'Oréal Issues Voluntary Recall of Benzoyl Peroxide Products Over Benzene Concerns

The recall includes L'Oréal's Effaclar Duo product. Stay tuned for more updates throughout the day.

Celebrating Second Annual National Dermatologist Day with Launch of EltaMD’s ‘Derm Difference’ Campaign

EltaMD’s Derm Difference campaign honors dermatologists’ expertise in skin health, cancer prevention, and confidence-boosting care.

Q&A: How the PWRS Program and Inaugural Report is Empowering Women and Transforming Global Healthcare

Eve Arnera and Thandiwe Munaiwa, MD, spoke about the groundbreaking collaboration between SkinCeuticals and ReSurge International, “Pioneering Women in Reconstructive Surgery.”

Quoin Files US Patent Applications for Rare Disease Treatments

The novel treatments will be for patients with orphan conditions like Netherton Syndrome, Peeling Skin Syndrome, SAM Syndrome, and palmoplantar keratoderma.

Strides for Skin Health Equity

LaShell Robinson on Takeda’s Initiative to Improve Research Diversity

Robinson shared insights into how the company is working to fight clinical research disparities.

National Eczema Association Expands Visual Guide to Address Skin Tone Disparities

Wendy Smith Begolka, MBS, and Renata Block, MMS, PA-C discuss the NEA's expanded eczema visual guide and upcoming Chicago event to support diverse patient communities.

Improving Social Determinants of Health Essential for Better AD Outcomes in Pediatric Patients of Color

Amid limited access to pediatric dermatologists nationwide, pediatric patients of color with atopic dermatitis are particularly affected by social determinants of health, further impacting their outcomes.

Addressing the Challenges of Pigmentary Disorders in Women Across the Fitzpatrick Skin Spectrum

Valerie Harvey, MD, MPH, FAAD, discusses pigmentary disorders like melasma and hyperpigmentation, highlighting their disproportionate impact on women, particularly those with skin of color.

Don’t miss a moment of Dermatology Times by signing up for our eNewsletters and subscribing to receive the free print issue and supplements each month.